Claire Fraser
Known title: DirectorCIK: 0001382031
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
Transaction History
| WAT | ▲ Buy | Grant | 358 | $0 | 2/25/2026 | View on chart |
| BDX | ▼ Sell | Open Market | 917 | $172K | 9/10/2025 | View on chart |
| BDX | ▼ Sell | Open Market | 863 | $166K | 8/8/2025 | View on chart |
| BDX | ▲ Buy | Grant | 930 | $0 | 1/28/2025 | View on chart |
| BDX | ▲ Buy | Grant | 900 | $0 | 1/23/2024 | View on chart |
| BDX | ▼ Sell | Open Market | 848 | $239K | 8/28/2023 | View on chart |
| BDX | ▲ Buy | Grant | 848 | $0 | 1/26/2023 | View on chart |
| BDX | ▼ Sell | Open Market | 841 | $228K | 2/8/2022 | View on chart |
| BDX | ▲ Buy | Grant | 820 | $0 | 1/25/2022 | View on chart |
| BDX | ▼ Sell | Open Market | 387 | $97K | 8/18/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Waters Launches AI Link for LC-MS Workflows
Waters Corporation introduced AI Link, a tool designed to advance AI-enabled LC-MS workflows from research to release. This product launch highlights the company's focus on integrating artificial intelligence into its laboratory solutions. Additionally, TD Cowen raised its price target to $515, reflecting continued analyst interest in the stock's potential.
Waters Launches AI Link for LC-MS Workflows. Waters Corporation introduced AI Link, a tool designed to advance AI-enabled LC-MS workflows from research to release. This product launch highlights the company's focus on integrating artificial intelligence into its laboratory solutions. Additionally, TD Cowen raised its price target to $515, reflecting continued analyst interest in the stock's potential.